[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1993

Intraoperative Autotransfusion in Hepatic Resection for Malignancy: Is It Safe?

Author Affiliations

From the Division of Surgical Oncology, Department of Surgery (Drs Zulim, Rocco, Goodnight, and Schneider), University of California, Davis Cancer Center and the University of California, Davis; the Department of Surgery, Kaiser North Medical Center, Sacramento, Calif (Dr Smith); and the Department of Surgery, University of Vermont Medical Center, Burlington (Dr Krag).

Arch Surg. 1993;128(2):206-211. doi:10.1001/archsurg.1993.01420140083013
Abstract

• To evaluate whether intraoperative autologous transfusion increases the risk of hematogenous dissemination of tumor we reviewed the risk of lung metastasis as well as disease-free and long-term survival of patients who underwent resection of malignant hepatic neoplasms with this technique. A retrospective review of patients undergoing liver resection for malignant disease revealed 39 patients in whom intraoperative autologous transfusion was used. The 2-year actuarial survival in the patients in this series, as calculated with the Kaplan-Meier method, was predicted to be 75%. Two-year actuarial disease-free survival was predicted to be 28%, and the risk of developing lung metastasis at 3 years was estimated to be 40%. The predicted overall survival and risk of recurrence in this series compare favorably with published data for patients in whom intraoperative autologous transfusion was not used.

(Arch Surg. 1993;128:206-211)

×